Clinical TrialsThe AATD clinical trial is progressing and expanding, with two enrollment countries instead of one.
Drug DesignationKRRO-110 has been granted orphan drug designation by the European Medicines Agency, which is a positive development for its potential treatment of Alpha-1 Antitrypsin Deficiency.
Financial StrategyA tactical workforce reduction has been announced, extending Korro Bio's cash runway into 2027 without impacting pipeline efforts or timelines.